Journal
CURRENT TOPICS IN MEDICINAL CHEMISTRY
Volume 19, Issue 1, Pages 17-32Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1568026619666190201094952
Keywords
Chemokine Receptor; CXCR4; Imgaing; Theranostics; Radionuclides; SPECT
Categories
Funding
- National Natural Science Foundation of China [81701740]
Ask authors/readers for more resources
Malignant tumors are a major cause of death. The lack of methods that provide an early diagnosis and adequate treatment of cancers is the main obstacle to precision medicine. The C-X-C chemokine receptor 4 (CXCR4) is overexpressed in various tumors and plays a key role in tumor pathogenesis. Therefore, CXCR4-targeted molecular imaging can quickly and accurately detect and quantify CXCR4 abnormalities in real time. The expression level and activation status of CXCR4 are very important for screening susceptible populations and providing an accurate diagnosis and optimal treatment. In view of the fact that radionuclide-labeled peptides have become widely used for the diagnosis and treatment of tumors, this manuscript reviews the potential of different radionuclide-labeled peptide inhibitors for the targeted imaging of CXCR4-positive tumors and targeted treatment. The article also discusses the specificity and in vivo distribution of radionuclide-labeled peptide inhibitors, and translation of these inhibitors to the clinic.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available